Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefepime/enmetazobactam - Allecra Therapeutics

Drug Profile

Cefepime/enmetazobactam - Allecra Therapeutics

Alternative Names: AAI 101/cefepime; AAI 101/cefepime - Allecra Therapeutics; AAI-202; EMT/FEP; FEP/AAI101; FEP/EMT

Latest Information Update: 30 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allecra Therapeutics
  • Class Anti-infectives; Antibacterials; Beta-lactams; Sulfones
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urinary tract infections
  • Preclinical Gram-negative infections

Most Recent Events

  • 02 Oct 2019 Efficacy, adverse events and pharmacokinetics data from the phase II CACTUS trial in Urinary tract infections presented at the ID Week 2019 (IDW-2019)
  • 13 Apr 2019 Pharmacodynamics data from preclinical studies in Gram negative infections presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)
  • 26 Jun 2018 Phase-III clinical trials in Urinary tract infections (Complicated) in Hungary (IV) (EudraCT2017-004868-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top